NICE recommends prucalopride for chronic constipation in women
January 24, 2011 by admin
NICE has recommended prucalopride as an option in certain circumstances for women with chronic constipation: treatment with at least two laxatives from different classes, at the highest tolerated recommended dose for at least six months, must have failed to provide adequate relief; and invasive treatment is being considered.
If prucalopride is not effective after 4 weeks, the woman should be examined again and the treatment reconsidered. Only clinicians with experience in treating chronic constipation should prescribe prucalopride, and they should review previous treatments carefully first.
NICE consults on diabetes and glaucoma draft quality standards
November 10, 2010 by admin
New draft quality standards for diabetes in adults and glaucoma have been published by NICE and comments invited.
New NICE guidance
November 10, 2010 by admin
NICE published several pieces of new guidance and appraisals in October, including a technology appraisal of liraglutide for the treatment of type 2 diabetes which recommends its use in both dual and triple therapy in some circumstances at a maximum daily dose of 1.2 mg but not 1.8 mg (see here for liraglutide details and here for a list of guidance by date).
Changes afoot for NICE/NPC
November 10, 2010 by admin
NICE is to lose its power to turn down new medicines for NHS use on the basis that they are too expensive for the benefits they offer, according to press reports. It will retain its role in producing guidelines but the NHS will move to a system of ‘value-based pricing’ to decide the costs of drugs, under government plans, with decisions taken by patients’ doctors and GP consortia. Lord Howe (Parliamentary Under Secretary of State for Quality - Lords) is reported to have told a trade body meeting in October that NICE was “somewhat redundant” when it came to cost-effectiveness decisions. The government’s White Paper set out NICE’s future role in developing quality standards in the future.
The news has received a mixed reaction, perhaps not surprisingly given the controversies over NICE’s role and decisions and the different interest groups involved.
The National Prescribing Centre (NPC) has announced that it is going to merge with NICE, that ministers have given approval, and that detailed discussions will start now with a view to the work being integrated by April 2011.
NICE issues new guidance
September 20, 2010 by admin
In August, NICE published guidance on some new topics: atrial fibrillation - dronedarone; Barrett’s oesophagus - ablative therapy; chronic heart failure; gastrointestinal stromal tumours - imatinib (adjuvant); hypertension in pregnancy; psoriatic arthritis - etanercept, infliximab and adalimumab; rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor; rheumatoid arthritis - tocilizumab; and transient loss of consciousness in adults and young people. An NPCi blog has explored some of the new guidance.
On 10 September, NICE also recommended liraglutide 1.2 mg daily for some people who have type 2 diabetes, in draft guidance. It sets out the circumstances in which liraglutide can be used in dual and triple therapy regimens and says that liraglutide 1.8 mg is not recommended. Final guidance is expected in October, says NICE.
BNF information to be part of NHS Evidence
April 10, 2009 by admin
Drug reference information from the BNF will form part of the new NHS Evidence portal, which is due to be launched in April. Responsibility for providing this information for the NHS, and for the contract for purchase of the BNF and the BNF for children in England, will transfer to NICE from the Department of Health.
Categories
Recent Posts
- Oral penicillin: children’s dosage recommendations
- RCN indemnity changes - further reactions
- No news is bad news on CD changes
- Where is the evidence base: NMP in primary care?
- Medicines for Children website launched
- NRLS to transfer to NHS Trust
- RCN indemnity changes
- Medicines legislation to be consolidated
- ANP annual conference: diversity, change and standards
- CD changes promised by end of October
Tags
- ANP ANP conference Carey N CD children CKS Clinical Knowledge Summaries consultation controlled drugs COPD cosmetic treatments Courtenay Courtenay M CPD dermatology DH diabetes district nurse prescriber generic substitution Home Office independent prescribers Matt Griffiths mental health MeReC MHRA Misuse of Drugs mixing medicines National Prescribing Centre NICE NMC non-medical prescribing NPC NPF NPSA Nurse prescribing Patient Group Directions PGD PGDs Prescribing RCN Royal Pharmaceutical Society Stenner Stenner K supplementary prescribers unlicensed medicines
